KRAS and bile duct cancer: To further investigate the immunogenicity of the KRAS Q61H mutation, we performed TCRseq on gDNA from FFPE-samples of various KRAS Q61H-positive tumors from 29 patients including 14 lung cancers, nine gastro-intestinal (including CRCs, pancreatic, and bile duct cancers), and six not otherwise specified tumors (others, Figure 5C, Supplementary Table S8).